Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Hereditary Sensory and Autonomic Neuropathies 3Small Cell Lung Carcinoma 2Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasms 1Metastatic Bladder Urothelial Carcinoma 1Leiomyosarcoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1Advanced Solid Tumor 1

Interventions

Doxorubicin 13Gemcitabine 10Ifosfamide 9Trabectedin 7Radiotherapy 7Docetaxel 5Dacarbazine 5pazopanib 3Sunitinib 3Sorafenib 3Nivolumab 3Filgrastim 3pembrolizumab 2pegfilgrastim 2liposomal doxorubicin 2eribulin 2cixutumumab 2belinostat 2Radiotherapy, Conformal 2Imatinib Mesylate 2Chemotherapy, Adjuvant 2Bevacizumab 2tremelimumab 1temsirolimus 1soblidotin 1selinexor 1sargramostim 1saracatinib 1rubitecan 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leiomyosarcoma × berzosertib × Clear all
NCT03718091 2023-07-07

M6620 (VX-970) in Selected Solid Tumors

Massachusetts General Hospital

Phase 2 Completed
30 enrolled 15 charts
Sarcoma

Leiomyosarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡